Who is sponsoring NCT04881396?

NCT04881396 is sponsored by Hospices Civils de Lyon.

What drugs are being tested in NCT04881396?

Interventions in NCT04881396: Evaluation of the immunogenicity of the vaccine in haemodialysis patients.

What condition does NCT04881396 study?

NCT04881396 studies COVID-19 Vaccines, Hemodialysis Complication.

Is NCT04881396 still recruiting?

NCT04881396 is currently completed. Last updated 10 May 2022.

Last reviewed 2022-05-10 · How we verify

NCT04881396: ROMANOV

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Response of Haemodialysis Patients to BNT162b2 mRNA Cov-19 Vaccine

Completed Last updated 10 May 2022

What this trial tests

trial testing Evaluation of the immunogenicity of the vaccine in haemodialysis patients in COVID-19 Vaccines in 99 participants. Completed in 15 February 2022.

Timeline

10 May 2021

Primary endpoint
15 February 2022

15 February 2022

Quick facts

Lead sponsor	Hospices Civils de Lyon
Status	Completed
Study type	OBSERVATIONAL
Enrollment	99
Start date	10 May 2021
Primary completion	15 February 2022
Estimated completion	15 February 2022
Sites	2 locations across France

Drugs / interventions tested

Evaluation of the immunogenicity of the vaccine in haemodialysis patients — full drug profile →

Conditions studied

COVID-19 Vaccines — all drugs for COVID-19 Vaccines →
Hemodialysis Complication — all drugs for Hemodialysis Complication →

Sponsor

Hospices Civils de Lyon — full company profile →

Who can join

Adults 18 to 130, any sex, with COVID-19 Vaccines or Hemodialysis Complication. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Vaccination against SARS-Cov2 is a necessity for haemodialysis patients because difficulties to maintain a self-isolation (leading to a higher contamination than general population) and an increase of mortality in case of contamination (more than 20% of mortality in this population). However, vaccine efficiency is known to be decreased in haemodialysis patients. This lead critical the rapid description of immunogenicity of anti SARS-Cov2 vaccine in haemodialysis patients. The aim of this study is to describe the immunogenicity of the BTN162b2 SARS-Cov2 vaccine in haemodialysis patients.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis.
Espi M, Charmetant X, Barba T, Mathieu C, et al · · 2022 · cited 72× · PMID 34856313 · DOI 10.1016/j.kint.2021.10.040
SARS-CoV-2 vaccination in patients receiving kidney replacement therapies: where are we now with the protective immune response?
Toapanta N, Bestard O, Soler MJ. · · 2021 · cited 5× · PMID 34289072 · DOI 10.1093/ndt/gfab227
Justification, safety, and efficacy of a third dose of mRNA vaccine in maintenance hemodialysis patients: a prospective observational study
Espi M, Charmetant X, Barba T, Pelletier C, et al · · 2021 · cited 2× · DOI 10.1101/2021.07.02.21259913

Verify or expand the search:

Other recruiting trials for COVID-19 Vaccines

Currently open trials in the same condition.

NCT06923137 — A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much · active not recruiting
NCT05556720 — Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Contro · Phase 3 · active not recruiting
NCT05096260 — Getting to Yes, Michigan! (G2YMI) · NA · active not recruiting

Other Hospices Civils de Lyon trials

Trials by the same sponsor.

NCT07569536 — Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock · Phase 3 · not yet recruiting
NCT07529314 — Evaluating Interventional Radiology for Cancer Pain Management · NA · not yet recruiting
NCT07273929 — Comparative Study of the Effectiveness of Three Access Routes for Implanting an Electronic Intracardiac Device · Phase 3 · not yet recruiting
NCT07474532 — Attitudes and Beliefs Related to Benzodiazepine Deprescribing · not yet recruiting
NCT07313007 — Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04881396 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospices Civils de Lyon
Last refreshed: 10 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04881396.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing